Informed Consent
Item
1. provision of written informed consent.
boolean
C0021430 (UMLS CUI [1])
Gender | Age | Prostate carcinoma
Item
2. men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0600139 (UMLS CUI [3])
Total Androgen Blockade
Item
3. history of treatment by complete androgen blockade for greater than 3 months prior to enrollment
boolean
C2986598 (UMLS CUI [1])
Progressive Disease | Raised prostate specific antigen Quantity | Prostate specific antigen measurement
Item
4. progressive disease evidenced by 2 consecutive rises in psa measured at least 1 week apart, with the absolute value of the latest psa > 5.0 ng/ml.
boolean
C1335499 (UMLS CUI [1])
C0178415 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0201544 (UMLS CUI [3])
Raised prostate specific antigen | Status post Androgen Antagonist Withdrawal
Item
5. a rise in psa following anti-androgen drug withdrawal, above the last psa value before withdrawal.
boolean
C0178415 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0002842 (UMLS CUI [2,2])
C2349954 (UMLS CUI [2,3])
Therapeutic procedure Hormone refractory prostate cancer | Chemotherapy Docetaxel Based | Chemotherapy Cabazitaxel Based | Chemotherapy Mitoxantrone Based | abiraterone | Radium-223 | enzalutamide | sipuleucel-T
Item
6. patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. treatments indicated for hrpc are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-t.
boolean
C0087111 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C1705938 (UMLS CUI [2,3])
C0392920 (UMLS CUI [3,1])
C2830183 (UMLS CUI [3,2])
C1705938 (UMLS CUI [3,3])
C0392920 (UMLS CUI [4,1])
C0026259 (UMLS CUI [4,2])
C1705938 (UMLS CUI [4,3])
C0754011 (UMLS CUI [5])
C0303282 (UMLS CUI [6])
C3496793 (UMLS CUI [7])
C1706668 (UMLS CUI [8])
Cancer Other | Exception Basal cell carcinoma | Exception Superficial transitional cell carcinoma of bladder
Item
1. other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0279680 (UMLS CUI [3,2])
C0205124 (UMLS CUI [3,3])
Medical condition Serious Impairing Imaging
Item
2. serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging.
boolean
C3843040 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0221099 (UMLS CUI [1,3])
C0011923 (UMLS CUI [1,4])
High weight
Item
3. patient weighs over 350 lbs (due to scanner weight limit).
boolean
C0948775 (UMLS CUI [1])
Life Expectancy
Item
4. clinical life expectancy < 12 weeks.
boolean
C0023671 (UMLS CUI [1])
Study Subject Participation Status | Radiopharmaceuticals Cumulative Dose per year Estimated
Item
5. participated in other radioactive drug studies where estimated total cumulative dose within 1 year is > 0.05 sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 sievert for other organs.
boolean
C2348568 (UMLS CUI [1])
C0182638 (UMLS CUI [2,1])
C2986497 (UMLS CUI [2,2])
C0439508 (UMLS CUI [2,3])
C0750572 (UMLS CUI [2,4])
Concurrent therapy allowed | Prior Chemotherapy allowed | Hormone Therapy | Prior surgery | Diphosphonates | Biological agents allowed
Item
6. concurrent therapy. allowed: prior or concurrent chemotherapy, but must be > 12 weeks since last treatment at enrollment; prior or concurrent hormonal therapy; prior surgery; prior or concurrent bisphosphonate; prior or concurrent receptor/biologic agent allowed if given on approved study protocol.
boolean
C0009429 (UMLS CUI [1,1])
C0683607 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0279025 (UMLS CUI [3])
C0455610 (UMLS CUI [4])
C0012544 (UMLS CUI [5])
C0005515 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])